Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) Director Ra Capital Management, L.P. purchased 341,742 shares of Janux Therapeutics stock in a transaction dated Wednesday, March 5th. The shares were purchased at an average cost of $30.64 per share, for a total transaction of $10,470,974.88. Following the completion of the transaction, the director now owns 9,658,988 shares of the company's stock, valued at approximately $295,951,392.32. This represents a 3.67 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Friday, March 7th, Ra Capital Management, L.P. bought 110,206 shares of Janux Therapeutics stock. The shares were acquired at an average price of $31.02 per share, with a total value of $3,418,590.12.
Janux Therapeutics Trading Down 2.4 %
Shares of JANX stock traded down $0.73 during trading hours on Tuesday, reaching $29.49. 453,113 shares of the company's stock were exchanged, compared to its average volume of 817,161. The company has a market cap of $1.74 billion, a price-to-earnings ratio of -24.95 and a beta of 3.23. Janux Therapeutics, Inc. has a fifty-two week low of $28.96 and a fifty-two week high of $71.71. The stock's 50 day moving average is $40.83 and its 200-day moving average is $47.40.
Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Equities analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current year.
Institutional Trading of Janux Therapeutics
A number of large investors have recently modified their holdings of JANX. Russell Investments Group Ltd. lifted its position in Janux Therapeutics by 77.7% in the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after acquiring an additional 442 shares during the last quarter. GF Fund Management CO. LTD. acquired a new stake in Janux Therapeutics in the 4th quarter valued at about $59,000. Plato Investment Management Ltd increased its stake in shares of Janux Therapeutics by 18.7% during the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company's stock worth $54,000 after purchasing an additional 187 shares in the last quarter. Avanza Fonder AB acquired a new stake in shares of Janux Therapeutics during the 4th quarter worth about $139,000. Finally, Meeder Asset Management Inc. purchased a new stake in shares of Janux Therapeutics in the fourth quarter valued at $159,000. Hedge funds and other institutional investors own 75.39% of the company's stock.
Wall Street Analyst Weigh In
JANX has been the subject of a number of recent analyst reports. William Blair reaffirmed an "outperform" rating on shares of Janux Therapeutics in a research report on Friday, January 10th. Leerink Partners boosted their target price on Janux Therapeutics from $79.00 to $91.00 and gave the stock an "outperform" rating in a research note on Tuesday, December 3rd. HC Wainwright reissued a "buy" rating and set a $70.00 target price on shares of Janux Therapeutics in a report on Monday, March 3rd. Stifel Nicolaus upped their price target on shares of Janux Therapeutics from $70.00 to $115.00 and gave the company a "buy" rating in a research report on Tuesday, December 3rd. Finally, Wedbush reissued an "outperform" rating and set a $76.00 price objective (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, Janux Therapeutics currently has a consensus rating of "Buy" and an average target price of $88.00.
Check Out Our Latest Analysis on JANX
Janux Therapeutics Company Profile
(
Get Free Report)
Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
See Also
Before you consider Janux Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Janux Therapeutics wasn't on the list.
While Janux Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
